Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen, Samsung Bioepis Get FDA OK for Lucentis Biosimilar

09/20/2021 | 06:06am EDT

By Colin Kellaher

Biogen Inc. and its Samsung Bioepis Co. venture on Monday said the U.S. Food and Drug Administration approved Byooviz, their biosimilar to Roche Holdings AG's blockbuster eye drug Lucentis.

The companies said the approval, the first in the U.S. for an ophthalmology biosimilar, covers Byooviz for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion and myopic choroidal neovascularization.

Biosimilars are near-copies of biologic drugs that are made from living cells and are analogous to generic copies of traditional pill-form medicines.

Byooviz was developed by Samsung Bioepis, a joint venture between Biogen and Samsung BioLogics Co., and be commercialized in the U.S. by Biogen. The companies said Biogen would be able to market Byooviz in the U.S. as of June 2022 under a global license agreement with Roche's Genentech unit, which developed Lucentis.

Biogen and Samsung Bioepis are also pursuing a biosimilar to Regeneron Pharmaceuticals Inc.'s blockbuster eye drug Eylea.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

09-20-21 0806ET

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -1.43% 281.19 Delayed Quote.14.84%
ROCHE HOLDING AG 0.08% 360.4 Delayed Quote.16.59%
SAMSUNG BIOLOGICS CO.,LTD. 1.16% 869000 End-of-day quote.5.21%
All news about BIOGEN INC.
10/17BIOGEN : Announces Topline Results from the Tofersen Phase 3 Study†and its Open-Label Exte..
10/17BIOGEN : trial of ALS drug fails main goal, but company says data are encouraging
10/15BIOGEN : Stifel Adjusts Biogen's Price Target to $344 from $430, Keeps Buy Rating
10/15BIOGEN : Cantor Fitzgerald Adjusts Price Target on Biogen to $327 From $427, Maintains Neu..
10/15Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
10/15Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
10/14BIOGEN : Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-..
10/14Biogen Inc. Announces Topline Results from Tofersen Phase 3 Study and Its Open Label Ex..
10/14BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
10/14BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 771 M - -
Net income 2021 1 954 M - -
Net Debt 2021 1 575 M - -
P/E ratio 2021 21,6x
Yield 2021 -
Capitalization 41 907 M 41 907 M -
EV / Sales 2021 4,04x
EV / Sales 2022 3,64x
Nbr of Employees 9 100
Free-Float 84,9%
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 281,19 $
Average target price 397,62 $
Spread / Average Target 41,4%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors